H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented: "With the November 18 Prescription Drug User Fee Act (PDUFA) action date for plozasiran in familial chylomicronemia syndrome (FCS) approaching, we conducted several calls with Arrowhead management and key opinion leaders (KOLs) in the space. Management emphasized that launch readiness is on track and the commercial buildout is nearly complete. Importantly, plozasiran represents both Arrowhead’s first commercial opportunity and a foundation for subsequent cardiometabolic launches, with management commentary focused on sales force hiring, payer engagement, patient identification initiatives, global planning, and other topics. KOLs have reinforced the magnitude of unmet need in FCS and the differentiation of RNAi therapies, describing APOC3 inhibition as mechanistically rational, clinically transformative, and particularly compelling when paired with the convenience of quarterly dosing, while noting plozasiran’s potential positioning as a best-in-class triglyceride-lowering therapy. As such, ahead of the November 18 PDUFA, we reiterate our Buy rating and $80 price target on ARWR."

For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.

Shares of Arrowhead Pharma closed at $36.54 yesterday.

You May Also Be Interested In

• Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
• Micron Technology (MU) PT Raised to $1,540 at JPMorgan
• RBC Capital Starts Enact Holdings Inc (ACT) at Sector Perform